vs
Side-by-side financial comparison of FirstCash Holdings, Inc. (FCFS) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $501.3M, roughly 1.4× FirstCash Holdings, Inc.). FirstCash Holdings, Inc. runs the higher net margin — 20.8% vs -104.7%, a 125.5% gap on every dollar of revenue. On growth, FirstCash Holdings, Inc. posted the faster year-over-year revenue change (21.2% vs -3.7%). Over the past eight quarters, FirstCash Holdings, Inc.'s revenue compounded faster (16.9% CAGR vs -2.9%).
FirstCash Holdings, Inc. is an American pawnshop company headquartered in Fort Worth, Texas which operates retail pawn stores in the U.S. and Latin America. It is a publicly traded company listed on the Nasdaq stock exchange.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
FCFS vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $501.3M | $699.9M |
| Net Profit | $104.2M | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | 28.5% | -100.7% |
| Net Margin | 20.8% | -104.7% |
| Revenue YoY | 21.2% | -3.7% |
| Net Profit YoY | 24.7% | -3583.4% |
| EPS (diluted) | $2.35 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $501.3M | — | ||
| Q3 25 | $411.0M | $699.9M | ||
| Q2 25 | $385.1M | $613.9M | ||
| Q1 25 | $371.1M | $692.8M | ||
| Q4 24 | $413.7M | $707.8M | ||
| Q3 24 | $363.1M | $727.1M | ||
| Q2 24 | $363.5M | $637.0M | ||
| Q1 24 | $366.8M | $711.0M |
| Q4 25 | $104.2M | — | ||
| Q3 25 | $82.8M | $-733.0M | ||
| Q2 25 | $59.8M | $-255.4M | ||
| Q1 25 | $83.6M | $-12.7M | ||
| Q4 24 | $83.5M | $-178.4M | ||
| Q3 24 | $64.8M | $-19.9M | ||
| Q2 24 | $49.1M | $-147.7M | ||
| Q1 24 | $61.4M | $-1.7B |
| Q4 25 | 28.5% | — | ||
| Q3 25 | 27.4% | -100.7% | ||
| Q2 25 | 21.1% | -29.4% | ||
| Q1 25 | 30.0% | 4.7% | ||
| Q4 24 | 26.5% | -14.2% | ||
| Q3 24 | 23.5% | 2.1% | ||
| Q2 24 | 18.2% | -18.4% | ||
| Q1 24 | 22.3% | -247.3% |
| Q4 25 | 20.8% | — | ||
| Q3 25 | 20.1% | -104.7% | ||
| Q2 25 | 15.5% | -41.6% | ||
| Q1 25 | 22.5% | -1.8% | ||
| Q4 24 | 20.2% | -25.2% | ||
| Q3 24 | 17.9% | -2.7% | ||
| Q2 24 | 13.5% | -23.2% | ||
| Q1 24 | 16.7% | -239.9% |
| Q4 25 | $2.35 | — | ||
| Q3 25 | $1.86 | $-10.78 | ||
| Q2 25 | $1.34 | $-3.77 | ||
| Q1 25 | $1.87 | $-0.19 | ||
| Q4 24 | $1.86 | $-2.54 | ||
| Q3 24 | $1.44 | $-0.30 | ||
| Q2 24 | $1.08 | $-2.20 | ||
| Q1 24 | $1.35 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $125.2M | $98.1M |
| Total DebtLower is stronger | $2.2B | $2.5B |
| Stockholders' EquityBook value | $2.3B | $2.0B |
| Total Assets | $5.3B | $5.7B |
| Debt / EquityLower = less leverage | 0.98× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $125.2M | — | ||
| Q3 25 | $130.2M | $98.1M | ||
| Q2 25 | $101.5M | $151.7M | ||
| Q1 25 | $146.0M | $127.1M | ||
| Q4 24 | $175.1M | $98.3M | ||
| Q3 24 | $106.3M | $143.7M | ||
| Q2 24 | $113.7M | $107.0M | ||
| Q1 24 | $135.1M | $78.5M |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $2.5B | ||
| Q2 25 | $1.7B | $2.1B | ||
| Q1 25 | $1.7B | $2.1B | ||
| Q4 24 | $1.7B | $2.1B | ||
| Q3 24 | $1.7B | $2.2B | ||
| Q2 24 | $1.7B | $2.2B | ||
| Q1 24 | $1.5B | $2.2B |
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.2B | $2.0B | ||
| Q2 25 | $2.1B | $2.8B | ||
| Q1 25 | $2.1B | $3.0B | ||
| Q4 24 | $2.1B | $3.0B | ||
| Q3 24 | $2.0B | $3.2B | ||
| Q2 24 | $2.0B | $3.2B | ||
| Q1 24 | $2.0B | $3.3B |
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.2B | $5.7B | ||
| Q2 25 | $4.5B | $6.4B | ||
| Q1 25 | $4.4B | $6.5B | ||
| Q4 24 | $4.5B | $6.4B | ||
| Q3 24 | $4.4B | $6.8B | ||
| Q2 24 | $4.3B | $6.7B | ||
| Q1 24 | $4.2B | $6.7B |
| Q4 25 | 0.98× | — | ||
| Q3 25 | 1.01× | 1.23× | ||
| Q2 25 | 0.79× | 0.74× | ||
| Q1 25 | 0.83× | 0.70× | ||
| Q4 24 | 0.85× | 0.72× | ||
| Q3 24 | 0.87× | 0.68× | ||
| Q2 24 | 0.85× | 0.70× | ||
| Q1 24 | 0.75× | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $206.6M | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | — | 7.0% |
| Cash ConversionOCF / Net Profit | 1.98× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $206.6M | — | ||
| Q3 25 | $135.8M | $-45.5M | ||
| Q2 25 | $116.9M | $-46.8M | ||
| Q1 25 | $126.6M | $65.6M | ||
| Q4 24 | $198.1M | $63.7M | ||
| Q3 24 | $113.1M | $117.9M | ||
| Q2 24 | $106.2M | $-97.9M | ||
| Q1 24 | $122.5M | $-700.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-94.7M | ||
| Q2 25 | — | $-84.3M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | — | $71.4M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | — | $-66.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | — | -13.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -9.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 9.3% |
| Q4 25 | 1.98× | — | ||
| Q3 25 | 1.64× | — | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | 2.37× | — | ||
| Q3 24 | 1.74× | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | 2.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FCFS
| US Pawn Segment | $292.2M | 58% |
| Retail POS Payment Solutions | $209.8M | 42% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
